Text: http://www.biophoton.com/russianscience/russianscience/russianscience.htm Biophotonic Therapy uses light in an extracorporeal or intravenous mode to activate the chemiluminescence of the blood cells, a form of immunity inherited from humankind's distant oligocellular ancestors. BT has an instructive 80-year history; a range of modalities; well-characterized mechanisms of action; a wide array of indications; several counterindications; well-understood, limited side-effects in certain cases; and a scientific literature that now includes some 400 articles as well as a dozen books. No drug resistance to BT has ever been reported. In the extracorporeal mode, a measured amount of blood is drawn from a vein, exposed briefly to a light source--usually ultraviolet and some visible light--and reinfused. The activated blood cells thereupon stimulate a general chemiluminescence in the blood that tends to normalize biochemical parameters and, in infectious diseases, to activate the entire immune system. In intravenous mode, low-intensity laser light--generally at 632.8 nm--is directed through a waveguide into the blood, with the same effects. The original extracorporeal Biophotonic Therapy device has the status of a "pre-amendment device" from FDA, permitting it to be used for the treatment of some dozen indications, including certain disseminated infections. BT forms a central component of the science of biophotonics, which has recently received serious funding for the first time in the United States with a $40 million National Science Foundation grant, but which has been studied for 80 years in Russia and for decades in Germany. Of all pharmacological interventions, Biophotonic Therapy probably has the broadest effectiveness in terms of numbers of indications and capacity for healing action. By a wide margin, BT is the #1 phototherapeutic treatment of infectious diseases. It outperforms antibiotics and antivirals in various indications, above all in disseminated infections resistant to drug therapies. Although BT is administered with a device, it is actually a drug--the pharmacology of light. As such, BT has exceptional interest in terms of elucidating other pharmacological and physiological phenomena. Biophotonic Therapy is also known as Photoluminescence and, in Russia, where thousands of medical doctors employ it on a daily basis, as Quantum Hemotherapy. BT's old name, Ultraviolet Blood Irradiation, was very misleading in its suggestiveness, even to medical professionals who should have understood that dose and clinical outcomes--not suggestive vocabulary--are the relevant scientific facts. The biomedical research establishment, dominated by infectious disease specialists who are generally ignorant of photomedicine and biophotonics, has foolishly, unscientifically, and all-too-characteristically dismissed BT and rejected funding for testing it on such obvious targets as HIV and smallpox--shocking and indefensible conduct in the contexts of a devastating global HIV/AIDS epidemic and the current threat of smallpox as a bioterrorist weapon. Biophotonic Therapy holds high scientific significance as a model for explaining the mechanisms of a range of Complementary and Alternative energy therapies, including homeopathy, as well as serving as the gateway to comprehending the roles and mechanisms of the chemiluminescence of the blood cells in neuroscience and immunity. For further information on Biophotonic Therapy, three English-language books can be recommended: Kenneth J. Dillon. Close-to-Nature Medicine. Washington, D.C.: Scientia Press, 2003 (best for up-to-date information, for theory, and for associated phenomena--www.scientiapress.net) Kenneth J. Dillon. Healing Photons. Washington, D.C.: Scientia Press, 1998 (best for detailed accounts of clinical studies, including those from the Russian and German literature, and for the range of unusual indications for BT-- www.scientiapress.net) William C. Douglass. Into the Light. Atlanta: Second Opinion Publishers, 1993 (best for detailed summaries and texts of the American scientific literature on BT in the 1930s, 1940s, and 1950s--out of print but available in used versions)

See Also:

Source: